File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Treatment Outcome of Metastatic Neuroblastoma with Antiganglioside 2 Monoclonal Antibody (3F8): the Hong Kong Experience

TitleTreatment Outcome of Metastatic Neuroblastoma with Antiganglioside 2 Monoclonal Antibody (3F8): the Hong Kong Experience
Authors
Issue Date2009
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP), São Paulo, Brazil, October 5-9, 2009. In Pediatric Blood & Cancer, 2009, v. 53 n. 5, p. 731, Abstract no. O.069 How to Cite?
AbstractPurpose: The prognosis of metastatic neuroblastoma remains to be poor despiteintensive chemotherapy and radiation therapy. Immunotherapy with monoclonalantibody appears to provide an additional armamentarium to the current treatmentstrategy. We evaluated our experience in using this approach.Method: This is a prospective study from Jan 1996 to Dec 2007 and the results werecompared to our historical control from 1990 when a common data registry wasstarted. Uniform treatment protocol was adopted by 5 public hospitals since 1996. Ourtreatment was based on a modified N6 & N7 protocol adopted from MSKCC whichincluded intensive chemotherapyþautologous BMT þ/ immunotherapy withmurine monoclonal anti-ganglioside-2 antibody (3F8, anti-GD2 provided by MSKCCafter 1999) for patients with stage 4 neuroblastoma. The analysis of outcome was byKaplan-Meier analysis.Results: Within these 13 years, 61 children (all >12 months) with metastaticneuroblastoma were diagnosed. The 5 years PFS were 11.8% and 49.1% after treatedwith chemotherapy þ/ auto-PBSCT (n¼34) and chemotherapyþ auto-BMTþ3F8(n¼27) respectively (p¼0.009). Their median survival were 1.8 yrs vs. 4.9 yrsrespectively (p¼0.015). The most frequent encountered side effect of 3F8 wastransient but severe pain and allergic reaction. The median follow-up period is3.8 years and the minimal follow-up period is two year.Conclusion: Patients with stage 4 neuroblastoma treated with 3F8 antibody appearedto have a higher and longer survival as compared to the historical control. Other frompain which could readily be controlled with analgesic, the side effects were acceptablein our cohort.
DescriptionSIOP Awards Session
Persistent Identifierhttp://hdl.handle.net/10722/106600
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorChan, GCFen_HK
dc.contributor.authorShing, MMKen_HK
dc.contributor.authorLuk, CWen_HK
dc.contributor.authorLee, ACWen_HK
dc.contributor.authorLing, ASCen_HK
dc.contributor.authorLi, CKen_HK
dc.contributor.authorHa, SYen_HK
dc.date.accessioned2010-09-25T23:22:31Z-
dc.date.available2010-09-25T23:22:31Z-
dc.date.issued2009en_HK
dc.identifier.citationThe 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP), São Paulo, Brazil, October 5-9, 2009. In Pediatric Blood & Cancer, 2009, v. 53 n. 5, p. 731, Abstract no. O.069-
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/106600-
dc.descriptionSIOP Awards Session-
dc.description.abstractPurpose: The prognosis of metastatic neuroblastoma remains to be poor despiteintensive chemotherapy and radiation therapy. Immunotherapy with monoclonalantibody appears to provide an additional armamentarium to the current treatmentstrategy. We evaluated our experience in using this approach.Method: This is a prospective study from Jan 1996 to Dec 2007 and the results werecompared to our historical control from 1990 when a common data registry wasstarted. Uniform treatment protocol was adopted by 5 public hospitals since 1996. Ourtreatment was based on a modified N6 & N7 protocol adopted from MSKCC whichincluded intensive chemotherapyþautologous BMT þ/ immunotherapy withmurine monoclonal anti-ganglioside-2 antibody (3F8, anti-GD2 provided by MSKCCafter 1999) for patients with stage 4 neuroblastoma. The analysis of outcome was byKaplan-Meier analysis.Results: Within these 13 years, 61 children (all >12 months) with metastaticneuroblastoma were diagnosed. The 5 years PFS were 11.8% and 49.1% after treatedwith chemotherapy þ/ auto-PBSCT (n¼34) and chemotherapyþ auto-BMTþ3F8(n¼27) respectively (p¼0.009). Their median survival were 1.8 yrs vs. 4.9 yrsrespectively (p¼0.015). The most frequent encountered side effect of 3F8 wastransient but severe pain and allergic reaction. The median follow-up period is3.8 years and the minimal follow-up period is two year.Conclusion: Patients with stage 4 neuroblastoma treated with 3F8 antibody appearedto have a higher and longer survival as compared to the historical control. Other frompain which could readily be controlled with analgesic, the side effects were acceptablein our cohort.-
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_HK
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.rightsSpecial Statement for Preprint only Before publication: 'This is a preprint of an article accepted for publication in [The Journal of Pathology] Copyright © ([year]) ([Pathological Society of Great Britain and Ireland])'. After publication: the preprint notice should be amended to follows: 'This is a preprint of an article published in [include the complete citation information for the final version of the Contribution as published in the print edition of the Journal]' For Cochrane Library/ Cochrane Database of Systematic Reviews, add statement & acknowledgement : ‘This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 20XX, Issue X. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.’ Please include reference to the Review and hyperlink to the original version using the following format e.g. Authors. Title of Review. Cochrane Database of Systematic Reviews 20XX, Issue #. Art. No.: CD00XXXX. DOI: 10.1002/14651858.CD00XXXX (insert persistent link to the article by using the URL: http://dx.doi.org/10.1002/14651858.CD00XXXX) (This statement should refer to the most recent issue of the Cochrane Database of Systematic Reviews in which the Review published.)-
dc.titleTreatment Outcome of Metastatic Neuroblastoma with Antiganglioside 2 Monoclonal Antibody (3F8): the Hong Kong Experienceen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailChan, GCF: gcfchan@hku.hken_HK
dc.identifier.emailLuk, CW: lukcwing@hkstar.com-
dc.identifier.emailLee, ACW: alvinscling@yahoo.com.hk-
dc.identifier.emailLi, CK: lichik@hku.hk-
dc.identifier.emailHa, SY: syha@hku.hk-
dc.identifier.authorityChan, GCF=rp00431en_HK
dc.identifier.doi10.1002/pbc.22234-
dc.identifier.hkuros163818en_HK
dc.identifier.hkuros179099-
dc.identifier.hkuros179100-
dc.identifier.hkuros167889-
dc.identifier.volume53-
dc.identifier.issue5-
dc.identifier.spage731-
dc.identifier.epage731-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats